MCKINNEY ROBERT A 4
4 · PROGENICS PHARMACEUTICALS INC · Filed Jan 5, 2011
Insider Transaction Report
Form 4
MCKINNEY ROBERT A
Chief Financial Officer
Transactions
- Award
ESPP (right to buy)
2011-01-03+6,337→ 6,337 totalExercise: $5.46From: 2011-07-01Exp: 2011-07-01→ Common Stock (6,337 underlying) - Tax Payment
Common Stock
2011-01-03$5.68/sh−2,473$14,047→ 44,886 total - Exercise/Conversion
ESPP (right to buy)
2011-01-03−2,715→ 0 totalExercise: $4.83From: 2011-01-01Exp: 2011-01-01→ Common Stock (2,715 underlying) - Exercise/Conversion
Common Stock
2011-01-03$4.83/sh+2,715$13,108→ 47,359 total
Footnotes (5)
- [F1]Acquired upon the complete exercise of a grant under the Non-Qualified Employee Stock Purchase Plan, which grant was previously reported at the start of a six month option term, to acquire common stock up to an option amount which is 25% of the optionee's quarterly salary less $6,250, at a purchase price equal to the lower of 100% of the market value on the date of grant or 85% of the market value on the date of exercise.
- [F2]Includes shares of common stock acquired from the non-reportable exercise of a Grant under the Qualified Employee Stock Purchase Plan.
- [F3]Granted under the Company's Non-Qualified Employeee Stock Purchase Plan.
- [F4]The option was granted on the first day of the option term and previously reported as a right to purchase shares of the Company's common stock at an exercise price equal to the market value on the date of grant. In accordance with the Non-Qualified Employee Stock Purchase Plan, the option is ultimately exercisable for an exercise price which is the lower of 100% of the market value on the grant date or 85% of the market value on the exercise date. The number of shares acquired upon exercise is based on the option amount divided by the lower of 100% of the market value on the grant date or 85% of the market value on the exercise date.
- [F5]The option will be exercisable for that number of shares equal to the option amount (25% of the optionee's quarterly salary less $6,250) divided by the lesser of the market value of the common stock on the grant date or 85% of the market value on the exercise date.